Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Novo Nordisk stock tumbled Friday — pulling Corbus Pharmaceuticals into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.Please watch the video at ...

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.